CArdioMetabolism and Atherosclerotic PlaqUe progreSsion

Launched by RUIJIN HOSPITAL · Nov 1, 2021

Keywords

ClinConnect Summary

This clinical trial, called CArdioMetabolism and Atherosclerotic Plaque progression, is studying how certain metabolic diseases, like diabetes and obesity, affect heart health, particularly the development of plaque in the arteries. The trial aims to enroll patients who have coronary artery disease along with conditions such as type 2 diabetes, prediabetes, obesity, and others. Researchers want to understand how these metabolic issues contribute to the progression of heart disease.

To participate in this study, individuals need to be between 18 and 80 years old and must have either coronary artery disease or specific metabolic disorders like type 2 diabetes, prediabetes, or obesity. However, people with severe liver failure, certain cancers, or serious infections, among other conditions, will not be eligible. Participants will be monitored to see how their metabolic conditions affect their heart health over time. This study is currently recruiting, and it's a great opportunity for those who meet the criteria to contribute to important research that could help improve treatments for heart disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-80 years
• * Established coronary artery disease or metabolic disorders, including:
• 1. Type 2 diabetes diagnosed by one of the following criteria:
• • HbA1c \>/= 6.5% Fasting plasma glucose \>/= 7.0 mmol/l (confirmed) 2h plasma glucose value during OGTT \>/= 11.1 mmol/l Already receiving glucose-lowering agents
• • 2. Prediabetes
• • 3. Obesity
• • 4. Chronic kidney disease
• • 5. Hyperuricemia
• • 6. Dyslipidemia
• Exclusion Criteria:
• • Severe liver failure (Child-Pugh grade B to C)
• • Severe anemia (hemoglobin \< 60g/L)
• • Familial hypercholesterolemia
• • Active malignant tumor
• • Active autoimmune diseases on corticosteroids
• • Acute or chronic infection
• • Life expectancy \< 1 year